ZA202304984B - Application of gypenosides combined with capsaicinoids in preparing medicines for preventing and/or treating nafld - Google Patents
Application of gypenosides combined with capsaicinoids in preparing medicines for preventing and/or treating nafldInfo
- Publication number
- ZA202304984B ZA202304984B ZA2023/04984A ZA202304984A ZA202304984B ZA 202304984 B ZA202304984 B ZA 202304984B ZA 2023/04984 A ZA2023/04984 A ZA 2023/04984A ZA 202304984 A ZA202304984 A ZA 202304984A ZA 202304984 B ZA202304984 B ZA 202304984B
- Authority
- ZA
- South Africa
- Prior art keywords
- gypenosides
- capsaicinoids
- application
- combined
- nafld
- Prior art date
Links
- FBFMBWCLBGQEBU-RXMALORBSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecah Chemical class O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FBFMBWCLBGQEBU-RXMALORBSA-N 0.000 title abstract 7
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 title abstract 7
- 229930187479 gypenoside Natural products 0.000 title abstract 7
- 239000003814 drug Substances 0.000 title abstract 3
- 229940079593 drug Drugs 0.000 title 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 5
- 238000010171 animal model Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/424—Gynostemma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses an application of gypenosides and capsaicinoids in preparing a medicine for preventing and/or treating NAFLD, and belongs to the technical field of biomedicine. In the invention, the gypenosides and the capsaicinoids are combined in an animal model for treating NAFLD, and the experimental results show that the combined application of the gypenosides and the capsaicinoids can significantly treat NAFLD compared with the single application of each medicine, and the combined application of the gypenosides and the capsaicinoids has obvious synergy. Therefore, the combination of gypenosides and capsaicinoids can provide reference for clinical treatment of NAFLD, and it is also expected to develop a combination of gypenosides and capsaicinoids for the treatment of NAFLD, which will have broad application prospects.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310337112.5A CN116211935A (en) | 2023-03-31 | 2023-03-31 | Application of gynostemma pentaphylla total glycosides and capsicum total alkaloids in preparing medicament for preventing and/or treating non-alcoholic fatty liver disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202304984B true ZA202304984B (en) | 2023-11-29 |
Family
ID=86580695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2023/04984A ZA202304984B (en) | 2023-03-31 | 2023-05-05 | Application of gypenosides combined with capsaicinoids in preparing medicines for preventing and/or treating nafld |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN116211935A (en) |
| ZA (1) | ZA202304984B (en) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104606275B (en) * | 2014-04-10 | 2017-03-29 | 宁波市第二医院 | A kind of lipotropic traditional Chinese medicine effective ingredient compositionss |
-
2023
- 2023-03-31 CN CN202310337112.5A patent/CN116211935A/en active Pending
- 2023-05-05 ZA ZA2023/04984A patent/ZA202304984B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN116211935A (en) | 2023-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022000027A (en) | Hemp extract for treatment of pain, cancer and epilepsy in animals. | |
| EA201650134A1 (en) | SPECIFIC COMBINED THERAPY OF MALIGNANT TUMORS BY CYTOSTATIC AND ITS MODIFIER | |
| BR0213906A (en) | Methods for producing an anti-angiogenic and / or vascular permeability reducing effect in a warm-blooded animal, and for treating cancer in a warm-blooded animal, pharmaceutical composition, kit, and use of zd6474 or one thereof pharmaceutically acceptable salt and a taxane | |
| MX2017006938A (en) | Combination therapy for treatment of cancer. | |
| PH12017500392A1 (en) | Medical treatments based on anamorelin | |
| NO20082566L (en) | Combination of AZ2171 and permetrexed | |
| BRPI0508982A (en) | use of azd2171 or a pharmaceutically acceptable salt thereof excluding an azd2171 maleate salt, pharmaceutical composition, kit, method for treating a cancer in a warm-blooded animal such as a human, and use of azd2171 maleate salt azd2171 and 5 - fu and cpt - 11 | |
| MX2019003751A (en) | Therapeutic protein. | |
| MX2021004207A (en) | Use of reboxetine to treat narcolepsy. | |
| BRPI0508959A (en) | use of azd2171 or a pharmaceutically acceptable salt of the same, use of azd2171 maleate salt and oxaliplatin, pharmaceutical composition, kit, and method for producing an antiangiogenic effect and / or reducing vascular permeability in a warm-blooded animal | |
| PH12018501769A1 (en) | Medicament for treatment of diabetic foot infections | |
| NO20064754L (en) | combination therapy | |
| MX2022001450A (en) | Method of treating cancer. | |
| ZA202304984B (en) | Application of gypenosides combined with capsaicinoids in preparing medicines for preventing and/or treating nafld | |
| BRPI0412408A (en) | methods for producing an antiangiogenic reducing effect and / or vascular permeability and for treating a cancer in a warm-blooded animal such as a human, pharmaceutical composition, kit, and use of azd2171 or a pharmaceutically acceptable salt thereof. and zd1839 or a pharmaceutically acceptable salt thereof. | |
| EA202190294A1 (en) | COMBINATION THERAPY FOR CANCER TREATMENT | |
| MX2021001084A (en) | Combination therapy for treating cancer. | |
| EA202190291A1 (en) | COMBINATION THERAPY FOR CANCER TREATMENT | |
| RU2009119225A (en) | METHOD OF TREATMENT AND PREVENTION OF COCKIDIOSIS OF MINK | |
| UA113183C2 (en) | METHOD OF ADIATION TREATMENT | |
| Eckmann | Thrombocytopenia, fever and chills: 2 case reports | |
| UA109848U (en) | METHOD OF TREATMENT OF PSORIASIS | |
| UA126583U (en) | METHOD OF TREATMENT OF PATIENTS WITH ERITATOMATIC-HEMORRAGIC BISHOP | |
| TH1701001134A (en) | The use of anabolin for the manufacture of drugs for the treatment of weight loss and conditions Involved in cancer patients | |
| Upasi | Homoeopathic remedies: the physics of healing with microdoses |